Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease

Yuyan Tan, Elaine Delvaux, Jennifer Nolz, Paul Coleman, Shengdi Chen, Diego Mastroeni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Histone deacetylase (HDAC) inhibitors have been widely reported to have considerable therapeutic potential in a host of neurodegenerative diseases. However, HDAC inhibitor selectivity and specificity in specific cell classes have been a source of much debate. To address the role of HDAC2 in specific cell classes, and in disease, we examined glial protein and mRNA levels in the substantia nigra (SN) of Parkinson's disease (PD) and normal controls (NCs) by immunohistochemistry and laser captured microdissection followed by quantitative real time polymerase chain reaction. Differential expression analysis in immunohistochemically defined laser capture microglia revealed significant upregulation of HDAC2 in the PD SN compared to NC subjects. Complementary in vivo evidence reveals significant upregulation of HDAC2 protein levels in PD SN microglia compared to NC subjects. Correspondingly, human immortalized telencephalic/mesencephalic microglial cells reveal significant upregulation of HDAC2 in the presence of the potent microglial activator lipopolysaccharide. These data provide evidence that selective inhibition of HDAC2 in PD SN microglia could be a promising approach to treat microglial-initiated nigral dopaminergic neuronal cell loss in PD.

Original languageEnglish (US)
Pages (from-to)134-141
Number of pages8
JournalNeurobiology of Aging
Volume68
DOIs
StatePublished - Aug 1 2018

Fingerprint

Histone Deacetylase 2
Microglia
Substantia Nigra
Parkinson Disease
Lasers
Up-Regulation
Histone Deacetylase Inhibitors
Telencephalon
Microdissection
Neuroglia
Neurodegenerative Diseases
Lipopolysaccharides
Real-Time Polymerase Chain Reaction
Proteins
Immunohistochemistry
Messenger RNA

ASJC Scopus subject areas

  • Neuroscience(all)
  • Aging
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease. / Tan, Yuyan; Delvaux, Elaine; Nolz, Jennifer; Coleman, Paul; Chen, Shengdi; Mastroeni, Diego.

In: Neurobiology of Aging, Vol. 68, 01.08.2018, p. 134-141.

Research output: Contribution to journalArticle

Tan, Yuyan ; Delvaux, Elaine ; Nolz, Jennifer ; Coleman, Paul ; Chen, Shengdi ; Mastroeni, Diego. / Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease. In: Neurobiology of Aging. 2018 ; Vol. 68. pp. 134-141.
@article{60357285d9e44c59a3ab5afb7dbf2276,
title = "Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease",
abstract = "Histone deacetylase (HDAC) inhibitors have been widely reported to have considerable therapeutic potential in a host of neurodegenerative diseases. However, HDAC inhibitor selectivity and specificity in specific cell classes have been a source of much debate. To address the role of HDAC2 in specific cell classes, and in disease, we examined glial protein and mRNA levels in the substantia nigra (SN) of Parkinson's disease (PD) and normal controls (NCs) by immunohistochemistry and laser captured microdissection followed by quantitative real time polymerase chain reaction. Differential expression analysis in immunohistochemically defined laser capture microglia revealed significant upregulation of HDAC2 in the PD SN compared to NC subjects. Complementary in vivo evidence reveals significant upregulation of HDAC2 protein levels in PD SN microglia compared to NC subjects. Correspondingly, human immortalized telencephalic/mesencephalic microglial cells reveal significant upregulation of HDAC2 in the presence of the potent microglial activator lipopolysaccharide. These data provide evidence that selective inhibition of HDAC2 in PD SN microglia could be a promising approach to treat microglial-initiated nigral dopaminergic neuronal cell loss in PD.",
author = "Yuyan Tan and Elaine Delvaux and Jennifer Nolz and Paul Coleman and Shengdi Chen and Diego Mastroeni",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.neurobiolaging.2018.02.018",
language = "English (US)",
volume = "68",
pages = "134--141",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Upregulation of histone deacetylase 2 in laser capture nigral microglia in Parkinson's disease

AU - Tan, Yuyan

AU - Delvaux, Elaine

AU - Nolz, Jennifer

AU - Coleman, Paul

AU - Chen, Shengdi

AU - Mastroeni, Diego

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Histone deacetylase (HDAC) inhibitors have been widely reported to have considerable therapeutic potential in a host of neurodegenerative diseases. However, HDAC inhibitor selectivity and specificity in specific cell classes have been a source of much debate. To address the role of HDAC2 in specific cell classes, and in disease, we examined glial protein and mRNA levels in the substantia nigra (SN) of Parkinson's disease (PD) and normal controls (NCs) by immunohistochemistry and laser captured microdissection followed by quantitative real time polymerase chain reaction. Differential expression analysis in immunohistochemically defined laser capture microglia revealed significant upregulation of HDAC2 in the PD SN compared to NC subjects. Complementary in vivo evidence reveals significant upregulation of HDAC2 protein levels in PD SN microglia compared to NC subjects. Correspondingly, human immortalized telencephalic/mesencephalic microglial cells reveal significant upregulation of HDAC2 in the presence of the potent microglial activator lipopolysaccharide. These data provide evidence that selective inhibition of HDAC2 in PD SN microglia could be a promising approach to treat microglial-initiated nigral dopaminergic neuronal cell loss in PD.

AB - Histone deacetylase (HDAC) inhibitors have been widely reported to have considerable therapeutic potential in a host of neurodegenerative diseases. However, HDAC inhibitor selectivity and specificity in specific cell classes have been a source of much debate. To address the role of HDAC2 in specific cell classes, and in disease, we examined glial protein and mRNA levels in the substantia nigra (SN) of Parkinson's disease (PD) and normal controls (NCs) by immunohistochemistry and laser captured microdissection followed by quantitative real time polymerase chain reaction. Differential expression analysis in immunohistochemically defined laser capture microglia revealed significant upregulation of HDAC2 in the PD SN compared to NC subjects. Complementary in vivo evidence reveals significant upregulation of HDAC2 protein levels in PD SN microglia compared to NC subjects. Correspondingly, human immortalized telencephalic/mesencephalic microglial cells reveal significant upregulation of HDAC2 in the presence of the potent microglial activator lipopolysaccharide. These data provide evidence that selective inhibition of HDAC2 in PD SN microglia could be a promising approach to treat microglial-initiated nigral dopaminergic neuronal cell loss in PD.

UR - http://www.scopus.com/inward/record.url?scp=85047273067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047273067&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2018.02.018

DO - 10.1016/j.neurobiolaging.2018.02.018

M3 - Article

C2 - 29803514

AN - SCOPUS:85047273067

VL - 68

SP - 134

EP - 141

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -